TiumBio’s Post

View organization page for TiumBio, graphic

307 followers

"We are thrilled that merigolix, a once-daily oral gonadotropin hormone-releasing hormone receptor antagonist, demonstrated clinically meaningful and statistically significant reductions in dysmenorrhea in its Phase 2a clinical trial for endometriosis. We are confident that this new molecule will be best-in-class not only for endometriosis but also for uterine fibroids." - Hun-Taek Kim, Ph.D., MBA, CEO of TiumBio #merigolix #endometiosis #women's health https://lnkd.in/gAgZcQk8

To view or add a comment, sign in

Explore topics